Presentation is loading. Please wait.

Presentation is loading. Please wait.

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,

Published byAlfred Lane Modified over 5 years ago

Similar presentations

Presentation on theme: "Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,"— Presentation transcript:

1 Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu, MD, Anne-Claire Toffart, MD, Denis Moro-Sibilot, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 8, Pages e1-e2 (August 2012) DOI: /JTO.0b013e318257fc1d Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, Chest CT scan howing lung disease in remission after treatment by crizotinib. B, Abdominal CT scan at the finish of crizotinib treatment without any liver lesion (a normal CT scan—January 12, 2011). CT, computed tomography. Journal of Thoracic Oncology 2012 7, e1-e2DOI: ( /JTO.0b013e318257fc1d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Chest CT scan performed 15 days after stopping crizotinib treatment showing flare- up disease with dramatic progression of left lung tumor (arrow); (B), Abdominal CT scan showing flare-up disease with the appearance of three liver metastasis (arrows). CT scan performed on June 14, 2011, 15 days after stopping crizotinib treatment. CT, computed tomography. Journal of Thoracic Oncology 2012 7, e1-e2DOI: ( /JTO.0b013e318257fc1d) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib  Oana Pop, MD, Augustin Pirvu,"

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 

Noriyasu Usami, MD, Shingo Iwano, MD, Kohei Yokoi, MD 
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib  Gouji Toyokawa, MD, PhD, Fumihiko Hirai, MD, PhD, Eiko.
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,

Leptomeningeal and Medullary Response to Second-Line Erlotinib in Lung Adenocarcinoma  Mathilde Wagner, MD, Benjamin Besse, MD, Corinne Balleyguier, MD,
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 

Transformation to Sarcomatoid Carcinoma in ALK-Rearranged Adenocarcinoma, Which Developed Acquired Resistance to Crizotinib and Received Subsequent Chemotherapies 
Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.

Response to Osimertinib in Choroidal Metastases from EGFRmt T790M–Positive Non– Small Cell Lung Adenocarcinoma  Filippo Gustavo Dall’Olio, MD, Celeste.
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A

Zeynep Eroglu, MD, Jae Kim, MD, Sharon Wilczynski, MD, PhD, Warren A
Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,

Long-Lasting Complete Remission with Tyrosine Kinase Inhibitor in Bronchioloalveolar Carcinoma with a so far Unknown EGFR Mutation  Vienna Ludovini, PhD,
Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer  Hiroyasu Kaneda, MD, PhD, Isamu.
A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib  Naoki Omachi, MD, Shigeki.

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib  Naoki Omachi, MD, Shigeki.
A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK  Satoshi Anai, MD, Masafumi.

A Case of Lung Adenocarcinoma Resistant to Crizotinib Harboring a Novel EML4-ALK Variant, Exon 6 of EML4 Fused to Exon 18 of ALK  Satoshi Anai, MD, Masafumi.

Similar presentations

Ads by Google